Lamprene (clofazimine) / Novartis - LARVOL DELTA

Genomic population structure, antimicrobial susceptibility, and clinical features of Mycobacterium xenopi isolates, Frankfurt, Germany, 1995-2020. (PubMed, J Clin Microbiol) - "Clofazimine and guideline-recommended antimycobacterial agents showed good in vitro efficacy, except rifampicin, with 23.6% resistance. The detection of closely related strains might point toward a common environmental source of infection. These findings highlight the need for continued surveillance and provide a comprehensive foundation that supports more accurate monitoring, improved understanding of disease behavior, and future investigations into M. xenopi pathogenicity."

Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

MYCOBACTERIUM ABSCESSUS AS A COMPLICATION OF IMMUNOSUPPRESSION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR CONGENITAL NEUTROPENIA (EBMT 2026) - "Despite treatment with systemic corticosteroids, ruxolitinib, ibrutinib, antiviral agents, and antifungal therapy for a probable invasive pulmonary aspergillosis infection, respiratory status continued to decline.By day +190, the patient presented with septic shock, for which invasive mechanical ventilation (IMV), fluid expansion and vasopressor therapy were required...BAL and blood cultures were positive for M. abscessus massiliense, confirming invasive pulmonary disease with bacteremia.Treatment consisted of intravenous amikacin, tigecycline, imipenem, and TDM guided azithromycin and clofazimine, in addition to ongoing antifungal therapy... This case illustrates how Mabs can emerge insidiously in pediatric alloSCT recipients, mimicking more common post-transplant complications and progressing rapidly to severe invasive infection. The patient's gradual recovery underscores the importance of early recognition, aggressive multidrug therapy, and careful reassessment of..."

Graft versus Host Disease • Hematological Disorders • Hepatology • Immunology • Infectious Disease • Inflammation • Neutropenia • Nontuberculous Mycobacterial Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • Septic Shock • Transplantation • CSF3R

Preserving the Antimycobacterial Drug Arsenal: A Case Report of Disseminated Mycobacterium Avium Disease (IWLH 2026) - "The patient was treated with clarithromycin, ethambutol, rifabutin, moxifloxacin, and cycloserine for two years, with amikacin added for the first six months, inducing ototoxicity...A salvage regimen was initiated, including amikacin, tedizolid, clofazimine, ceftazidime/avibactam, isoniazid, delamanide, and ethambutol, as well as antiepileptic treatment and IFNγ administration...Intravenous dexamethasone was administered with intensified NTM treatment, but blood cell counts continued to decline, and inflammatory markers (CRP, PCT) remained high. Due to previous Gram-negative infections, his regimen was modified to include daptomycin, meropenem/vaborbactam, and colistimethate. Candida glabrata was identified in port cultures, necessitating port removal and initiation of isavuconazole. He was placed on dual beta-lactam therapy (meropenem and ceftriaxone) combined with clofazimine, isoniazid, linezolid, cycloserine, bedaquiline, and pretomanid...Conclusions This case..."

Case report • Clinical • CNS Disorders • Epilepsy • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases • Septic Shock • IFNG • IL12A

Nanocarrier based Topical Gel of Clofazimine: Advanced Therapeutic Strategy for the Treatment of Leprosy. (PubMed, J Drug Target) - "Furthermore, formulation has good physicochemical stability with a shelf life of about 27 months. In conclusion the study suggests that NLC-loaded CLOF was applied topically to treat leprosy, providing improved skin penetration and effectiveness."

Journal

Metabolic shutdown of Mycobacterium avium in response to clofazimine and macrolide antibiotics (ESCMID Global 2026) - No abstract available

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Antibacterial activity of clofazimine and bedaquiline and mutations associated with resistance in the Mycobacterium avium complex and Mycobacterium abscessus complex (ESCMID Global 2026) - No abstract available

Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clofazimine use for non-tuberculous mycobacterial infections: ten-year experience in Belgium (ESCMID Global 2026) - No abstract available

Nontuberculous mycobacteria • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Treatment Outcomes of Clofazimine-Containing Regimens in Mycobacterium avium Complex Pulmonary Disease: a retrospective study from two European reference centers (IWLH 2026) - "Clofazimine-containing regimens for MAC-PD were well tolerated and achieved satisfactory outcomes across heterogeneous European cohorts. Despite inter-center demographic differences, treatment success and safety were comparable. These real-world findings support clofazimine's inclusion as a valuable adjunct in MAC-PD management and underscore the need for prospective multicenter studies to optimize dosing and long-term outcomes."

Retrospective data • Bronchiectasis • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Musculoskeletal Pain • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Pregnant women with MDR/RR-TB and the all-oral 6-month regimen: experiences from a patient series in South Africa. (PubMed, Clin Infect Dis) - "These limited data suggests that in pregnant women, the BDLLfx/BDLCfz regimens have improved treatment and pregnancy outcomes compared to prior regimens. However, there is a high prevalence of unfavourable infant outcomes."

Journal • Acute Respiratory Distress Syndrome • Hematological Disorders • Human Immunodeficiency Virus • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

An Exploratory Clinical Study on the Early Efficacy and Safety of JDB0131 Benzensulfonate Tablets in Patients with Multidrug-Resistant Tuberculosis (ChiCTR) - P=N/A | N=10 | Recruiting | Sponsor: West China Hospital, Sichuan University; WestVac Biopharma Co.,Ltd.

New trial • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Treatment strategies for Mycobacterium avium pulmonary disease. (PubMed, Breathe (Sheff)) - "compared rifampicin or clofazimine as adjuncts to ethambutol and a macrolide. Finally, Nguyen et al. conclude that a two-drug regimen may be a viable option for treating MAC infections."

Journal • Infectious Disease • Nontuberculous Mycobacterial Disease • Pulmonary Disease • Respiratory Diseases

Targeted Next-Generation Sequencing in Drug-Resistant Tuberculosis: WHO Guidance and Practical Implementation Priorities. (PubMed, Biomedicines) - "This review summarizes (i) the core tNGS principles and panel design; (ii) platform-specific workflows for Illumina and Nanopore, including direct-from-sample implementations and typical turnaround times; (iii) catalogue-based interpretation against the 2023 WHO Mycobacterium tuberculosis mutation catalogue, with emphasis on bedaquiline/clofazimine (BDQ/CFZ) resistance and management of uncertain variants; (iv) pooled accuracy and sources of genotype-phenotype discordance; and (v) practical requirements for bioinformatics, quality assurance/external quality assessment (QA/EQA), and standardized reporting. We summarize operational and economic considerations (throughput, batching, and network design) to clarify where tNGS adds value compared with alternative strategies and to outline priority research needs, including (i) performance standards for culture-free tNGS, (ii) robust heteroresistance detection, (iii) standardized variant curation, and (iv) data-sharing..."

Biomarker • Journal • Next-generation sequencing • Review • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Clofazimine-induced interstitial lung disease with haemoptysis during therapy for Mycobacterium abscessus pulmonary disease. (PubMed, BMJ Case Rep) - "She initially received intravenous imipenem and amikacin plus oral clarithromycin for 1 month, followed by maintenance therapy with clarithromycin and clofazimine (CFZ). This case illustrates CFZ-induced lung injury presenting with haemoptysis during therapy for M. abscessus pulmonary disease. Clinicians should be aware of this rare but significant complication, particularly in patients receiving long-term CFZ."

Journal • Cough • Fatigue • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases

Clinical Characteristics and Management of Non-Tuberculous Mycobacterial Skin and Soft Tissue Infections: A Retrospective Cohort Study. (PubMed, Open Forum Infect Dis) - "Azithromycin, the most prescribed drug, was discontinued prematurely because of toxicity in 35% (18/52) of patients, ethambutol in 33% (9/27), and clofazimine in only 12% (3/26). Immunocompromised status is associated with disseminated NTM-SSTI and worse treatment outcomes. Regardless of immune status, antimycobacterial drugs often cause toxicity, leading to treatment changes."

Journal • Retrospective data • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Tuberculosis diagnosis and the complete drug resistance pattern from a single sample within a single day by use of a composite platform of MAX MDR-TB and AmPORE-TB. (PubMed, J Clin Microbiol) - "Resistance profiling most frequently (up to 11.3%) failed for clofazimine, pretomanid, and delamanid. This approach is expected to markedly reduce morbidity, drop-out rates, and transmission. The necessary instruments and technologies are already available in many high-prevalence countries and are currently being rapidly scaled up worldwide."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Erythema Nodosum Leprosum Triggered by Herpes Simplex Infection: A Case Report. (PubMed, Cureus) - "The patient received antibiotics followed by anti-leprosy therapy (dapsone, clofazimine, rifampicin) and tapering corticosteroids, with complete resolution of symptoms. This case highlights the importance of considering leprosy and its immunologic reactions in acute facial eruptions."

Journal • Dermatology • Herpes Simplex • Immunology • Infectious Disease • Inflammation • Otorhinolaryngology • Primary Immunodeficiency

Efficacy of regimens targeting Mycobacterium abscessus in vitro and in vivo. (PubMed, BMC Microbiol) - "ABM and CBM regimens show great promise against Mabs in vivo. We strongly recommend carrying out additional clinical trials to explore their efficacy."

Journal • Preclinical • Infectious Disease • Nontuberculous Mycobacterial Disease • Respiratory Diseases

Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action. (PubMed, Indian J Dermatol Venereol Leprol) - "Resistance mechanisms include mutations in genes such as rpoB (rifampicin), folP1 (dapsone), and gyrA (ofloxacin)...Regional variations in resistance patterns necessitate localised surveillance to guide effective treatment strategies. Enhanced diagnostic capabilities, patient education, and policy-level interventions are essential to combat the rising threat of AMR in leprosy."

Journal • Dermatology

Pharmacokinetics of Inhaled Clofazimine Dry Powder in Healthy Mice. (PubMed, AAPS PharmSciTech) - "Biodistribution studies indicated preferential CFZ retention in lung and spleen tissue following both single and multiple inhaled doses. In conclusion, these results suggest the novel dry powder inhaled CFZ formulation can produce high therapeutic concentration in lung tissues for extended periods of time after single and multiple doses, thereby, underscoring the potential of using inhaled CFZ as the treatment of MDR-TB."

Journal • PK/PD data • Preclinical • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

"Six months is a lot of time to lie": Anticipated stigma, disclosure and treatment preferences among participants in a tuberculosis therapeutic trial. (PubMed, Res Sq) - P2 | "Clofazimine, a drug that can cause skin hyperpigmentation has been proposed as a component of shorter TB treatment regimens...Additional work is needed to delineate drivers of therapeutic preferences among people with TB. Trial Registration: NCT04311502, registered November 5, 2021."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Unraveling Drug Resistance in Mycobacterium leprae: Exploring Genetic Mutations to Enhance Treatment Strategies for Human Leprosy-A Narrative Review. (PubMed, Int J Microbiol) - "Although multidrug therapy comprising rifampicin, dapsone, and clofazimine remains the mainstay treatment recommended by the World Health Organization for leprosy and has proven to be highly effective in managing both multibacillary and paucibacillary forms, the treatment outcomes are hindered by drug resistance, adverse drug reactions, and poor adherence. This narrative review draws upon a comprehensive search of electronic databases to enhance understanding of the genetic mutations associated with drug resistance. It further highlights ongoing research into resistance mechanisms, novel therapeutic options, postexposure prophylaxis, and vaccine development, which are critical for sustaining the effectiveness of multidrug therapy and advancing global leprosy control efforts."

Journal • Review

TREATMENT NEGLECT IN MULTIBACILLARY LEPROSY LEADING TO OSTEOMYELITIS AND TRANSTIBIAL AMPUTATION: LESSONS FROM ENDEMIC SETTING. (PubMed, Int J Infect Dis) - "Multibacillary multidrug therapy was initiated; dapsone was temporarily withheld because of anemia, and rifampicin with clofazimine was administered. Despite antimicrobial therapy and wound management, the extent of infection necessitated surgical amputation to control disease progression. This case highlights the consequences of treatment neglect in multibacillary leprosy and underscores the importance of early therapeutic intervention, continuous care, and patient adherence to prevent severe disability in endemic settings."

Journal • Anesthesia • Hematological Disorders • Infectious Disease • Inflammation • Pain

Co-administering clofazimine with infant formula enhances its oral bioavailability in rats and pigs. (PubMed, Eur J Pharm Biopharm) - "Results from this study demonstrated that infant formula was an effective enabling formulation, with a positive correlation between improved drug solubilisation during in vitro digestion of infant formula and enhanced in vivo drug exposure following oral administration. Infant formula therefore offers an inexpensive and scalable formulation approach for improving the bioavailability of paediatric drugs, like clofazimine, and enabling the treatment of infections in children."

Journal • Preclinical • Infectious Disease • Pediatrics

Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes. (PubMed, BMC Microbiol) - No abstract available

Journal

Antibiotic dose-response curves can measure antibiotic activity against Mycobacterium abscessus and Mycobacterium peregrinum. (PubMed, bioRxiv) - "We used Clinical and Laboratory Standards Institute growth conditions for rapid-grower nontuberculous mycobacteria to generate 990 dose-response curves across three time points (72 hours, 96 hours, and 120 hours) for six guideline-recommended (clarithromycin, amikacin, cefoxitin, linezolid, tigecycline, and clofazimine) and five new (omadacycline, tedizolid, SPR719, SQ109, and bedaquiline) antibiotics against Mycobacterium abscessus subspecies abscessus ATCC 19977 and Mycobacterium peregrinum ATCC 700686. We identified time-dependent changes in dose-response curve metrics that allow the detection of inducible clarithromycin resistance with only five days of incubation. This study demonstrates the potential of dose-response curves in measuring antibiotic activity against Mycobacterium abscessus ."

Journal • Nontuberculous Mycobacterial Disease • Respiratory Diseases